0001453687-23-000083.txt : 20231115
0001453687-23-000083.hdr.sgml : 20231115
20231115171610
ACCESSION NUMBER: 0001453687-23-000083
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231113
FILED AS OF DATE: 20231115
DATE AS OF CHANGE: 20231115
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Myers Scott Dunseth
CENTRAL INDEX KEY: 0001356256
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37798
FILM NUMBER: 231411566
MAIL ADDRESS:
STREET 1: C/O CASCADIAN THERAPEUTICS, INC.
STREET 2: 3101 WESTERN AVE., SUITE 600
CITY: SEATTLE
STATE: WA
ZIP: 98121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cartesian Therapeutics, Inc.
CENTRAL INDEX KEY: 0001453687
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 65 GROVE STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617-923-1400
MAIL ADDRESS:
STREET 1: 65 GROVE STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: SELECTA BIOSCIENCES INC
DATE OF NAME CHANGE: 20090109
4
1
wk-form4_1700086561.xml
FORM 4
X0508
4
2023-11-13
0
0001453687
Cartesian Therapeutics, Inc.
RNAC
0001356256
Myers Scott Dunseth
C/O CARTESIAN THERAPEUTICS, INC.
65 GROVE STREET
WATERTOWN
MA
02472
1
0
0
0
0
Stock Option (Right to Buy)
2.10
2023-11-13
4
D
0
20000
D
2029-06-13
Common Stock
20000
0
D
Stock Option (Right to Buy)
3
2023-11-13
4
D
0
20000
D
2030-06-18
Common Stock
20000
0
D
Stock Option (Right to Buy)
4.01
2023-11-13
4
D
0
40000
D
2031-03-29
Common Stock
40000
0
D
Stock Option (Right to Buy)
3.31
2023-11-13
4
D
0
40000
D
2032-01-02
Common Stock
40000
0
D
Stock Option (Right to Buy)
1.13
2023-11-13
4
D
0
87500
0.93
D
2033-01-01
Common Stock
87500
0
D
This option, which provided for vesting in thirty-six (36) substantially equal monthly installments over three years following the date of grant on June 14, 2019, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc.
This option, which provided for vesting in full on June 17, 2021, was canceled in the Merger.
This option, which provided for vesting in full on March 30, 2022, was canceled in the Merger.
This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger.
This option, which provided for vesting in full on January 2, 2024, was canceled in the Merger in exchange for a cash payment of $81,375, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger.
/s/ Matthew Bartholomae, Attorney-in-Fact for Scott Dunseth Myers
2023-11-15